Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RORβ antagonist
- Development stage
- Preclinical
- Lead developer
- Orphagen Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
RORβ antagonist is a small-molecule therapeutic program developed by Orphagen Therapeutics that targets the nuclear receptor Retinoic acid receptor-related orphan receptor beta (RORβ). By antagonizing RORβ, the drug aims to inhibit the transcriptional activity and downstream signaling pathways that drive tumor growth and survival in specific malignancies. The program is currently in preclinical development, with primary focus areas including small cell lung cancer (SCLC) and hematologic cancers such as T-cell acute lymphoblastic leukemia (T-ALL).
- Other names
- RORβ antagonistsRORβ Antagonist
02
Targets
RORB (RORβ / RORB)
Beyond the preview
Go deeper on RORβ antagonist.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RORβ antagonist.